Objective: To evaluate continuing stiripentol treatment in adulthood in Dravet syndrome (DS). Method: Longitudinal data were collected from the last visit prior to age 15 years (V 15 y ) to the last visit in adulthood (V adult ) in the 40 DS patients (32 typical, eight atypical) of a French historical cohort (Paris) of subjects who continued stiripentol from childhood or adolescence to adulthood. Results: At V adult (18-40 years, median = 23 years), all the patients were still receiving stiripentol (exposure = 3-24 years, median = 18 years), associated with clobazam (40/40), valproate (39/40), and topiramate (21/40). Between V 15 y and V adult , stiripentol was interrupted in five patients (two for adverse events) but reintroduced following seizure aggravation. Loss of appetite affected 15 of 40 patients but resolved after reducing the dose of stiripentol or valproate; no other new stiripentol-related adverse events were reported. Mean stiripentol dose was progressively decreased from 39 to 25 mg/kg/d (P = 0.0002), whereas clobazam (0.27 mg/kg/d) and valproate (14 mg/ kg/d) remained stable. At V adult , 37 of 40 patients still had generalized tonic-clonic seizures, but none still had status epilepticus (vs three at V 15 y ) and only one had myoclonia. During adulthood, generalized tonic-clonic seizure frequency and duration continued to decrease (P = 0.02, P = 0.008) and 10 patients experienced seizure-free periods ≥ 1 years (up to 5 years). All patients already had intellectual disability at V 15 y , but retardation was more severe at V adult (P = 0.03). Furthermore, neurological/gait condition had declined (two patients became bedridden) and behavior had worsened (P < 0.0002). Nevertheless, the 33 patients on stiripentol from infancy/childhood (<15 years) tended to have better seizure outcome in midadulthood than the seven treated from adolescence (>15 years) and the DS patients treated from adult age or stiripentol-naive subjects reported in the literature. Significance: The efficacy and safety of the stiripentol/valproate/clobazam combination started at pediatric age are maintained at very long term during adulthood.
| INTRODUCTION
Stiripentol (STP), a γ-aminobutyric acidergic antiepileptic drug, has been approved in Europe, Japan, and Canada, in association with clobazam and valproate, for the treatment of generalized tonic-clonic seizures (GTCSs) in children with Dravet syndrome (DS). 1 The pivotal phase 3 randomized-controlled clinical trials included patients from 3 years of age, 2, 3 but there are supportive data in younger patients [4] [5] [6] so that STP is widely used from the first year of life, as soon as DS is suspected. By contrast, data on STP use are still scarce in adulthood. Notably, significant series of adult patients with DS (STP-naive) have been described only recently. [7] [8] [9] [10] Almost all these patients (85%-100%) continue to have GTCSs in adulthood, but at a lower frequency, and convulsive status epilepticus tends to disappear. All of them present with intellectual disability, but long-term prognosis seems less severe in atypical (no myoclonus, no absences) than in typical forms. 10 In addition, appropriate therapy during childhood could play a crucial role for epilepsy outcome in adulthood; seizures seem to persist at higher frequency and episodes of status epilepticus still occur if aggravating drugs were used for long periods during childhood, mainly due to late DS diagnosis. 9, 11 When adolescent DS patients receive STP, it is advised to continue the drug in adulthood if the patient is stabilized, 1 but longitudinal data from childhood to determine the very long-term effects and how to use it in adults are lacking. 12 We reported preliminary data in 12 patients, 11
still on STP at a median age of 21 years, and efficacy was maintained with relatively low seizure frequency (monthly to yearly) and no status epilepticus. 13, 14 The objective of the present study was to describe in detail the long-term course on STP through adulthood of the French historical cohort of DS patients treated from childhood or adolescence. Among them are the first cases treated with STP in the world, from 1992 on, 15 and 10 of those included in the pivotal phase 3 trial. 2 This is the first time so many patients on STP are reported for such a long follow-up.
| MATERIALS AND METHODS
Among the patients recruited at pediatric age at the Reference Center of Epilepsies in Paris (previously Saint Vincent de Paul Hospital, now Necker Hospital, Paris, France) since 1992 and diagnosed as having DS, we selected all those who fulfilled the following criteria: STP initiated in childhood or adolescence, STP continued in adulthood, at least one visit while on STP during childhood or adolescence, and at least one visit during adulthood (three patients had only one visit during adulthood). For this study, we considered the upper limit of adolescence to be 21 years, because it corresponded to the most frequent age of transition from pediatric to adult care in our practice with DS patients. 16 Files were reviewed by the same investigator (C.C.). The main characteristics of GTCSs (frequency, duration, severity, provoking factors), other seizure types (myoclonic, absences, focal, tonic), neurological/intellectual/behavioral status (determined by clinical assessment as mild/ moderate/severe), antiepileptic drugs (type, dose, adverse events) and other central nervous system drugs, standard electroencephalographic (EEG) reports (background as normal/slow/other, interictal spikes as diffuse/focal/both, photosensitivity), and sociomedical care status (institution, autonomy, rehabilitation) were collected globally during childhood and at each visit from the last visit before age 15 years up to the final visit in adulthood.
Data were anonymously collected and independently analyzed. A statistical descriptive analysis was applied to all variables. Paired comparisons between visits used the Wilcoxon signed-rank test for continuous variables (doses and number of seizures) and the exact McNemar paired test for discrete variables (all other variables). Changes were considered significant if P < 0.05 for the comparisons between two visits (last visit before adulthood and last visit in adulthood) and if P < 0.016 (Bonferroni correction) for the comparisons between three visits (last visit before age 15 years, last visit before adulthood, and last visit in adulthood).
| Patients
Forty patients (22 males, 18 females) were included. Most of them had been followed by three epileptologists (73% by C.C. during childhood, 49% by I.A., and 23% by M.H. during adulthood).
Key Points
• The efficacy and safety of the stiripentol/valproate/clobazam combination started in childhood are maintained at very long-term adulthood • On stiripentol from childhood, 25% of Dravet patients exhibited >1-year seizure-free periods during adulthood and none had status epilepticus after 25 years of age • Prolonged stiripentol therapy tends to positively impact the late prognosis of epilepsy, especially when initiated before adolescence
As expected in DS patients, the first seizure occurred during the first year of life, and was (tonic-)clonic, mostly febrile, and prolonged, whereas psychomotor development, neurological examination, and standard EEG were normal (moderate postural delay in one case; Table 1 ). Then, all patients continued to experience GTCSs during childhood, mostly unilateral, alternating from one side to the other, in clusters, prolonged as status epilepticus in 85% of them, and triggered most often by fever, effort, or emotions. Myoclonic seizures and absences were reported in respectively two-thirds and three-quarters of children, so that 32 of them were considered to have typical DS and eight to have atypical DS. Focal seizures were also frequently present, but tonic seizures were exceptional (two patients).
About one-third of patients had a family history of seizures or epilepsy. Two females were twins. A genetic examination was performed in 32 patients, mostly by direct sequencing, and in all cases after DS had been clinically diagnosed; SCN1A mutations were detected in 27 patients (only one truncating), PCDH19 and HCN2 in two others. Magnetic resonance imaging was negative in the 22 patients examined in childhood.
STP was initiated at a median age of 6.3 years (from 0.8 to 20.9 years), as an adjunctive therapy to clobazam and valproate in respectively all and all but one case, and before the age of 15 years in 79% of cases. There was a delay of 0.5-20.5 years (median = 5.9 years) between the first seizure and STP initiation. The two other antiepileptic drugs associated with STP for the longest period were topiramate and levetiracetam, which were interrupted before 15 age years mostly for adverse events regarding topiramate (5/7 withdrawals) and for lack of efficacy regarding levetiracetam (3/5 withdrawals). Before DS diagnosis and STP initiation, most of the other usual antiepileptic drugs had been prescribed, but they were rapidly interrupted in the event of seizure aggravation. The most frequent STPrelated adverse event was loss of appetite/loss of weight, which usually resolved when the STP and/or valproate dose was decreased, but led to STP being withdrawn in one patient before the age 10 years despite a certain efficacy (STP was reintroduced at age 17 years). the cases, at a median dose of 0.3, 12, and 2 mg/kg/d, respectively. Levetiracetam or clonazepam were also associated in three patients. Significant adverse events were reported in four patients, all of moderate intensity and not STP-related (loss of hair related to valproate, drowsiness and hypotonia related to clobazam overdosage, and cramps in the twins). All children but one were still experiencing GTCSs. Other seizure types were reported in <20% of children. In the majority of patients, GTCS frequency was <1/ wk (58%) and their duration was <1 minute (67%), both being predominantly reported as regular. Nevertheless, 28% of patients received rescue benzodiazepines and three still experienced status epilepticus. Unilateral and alternating seizures had almost disappeared, whereas GTCSs remained mostly provoked (83%, mostly by fever). They occurred in clusters in one-half of the patients, mostly during sleep in one-third, and were occasionally traumatic in one-fourth. EEG background was slow in 69% of patients, and only one had photosensitivity. The main neurological features included hypotonia, gait disturbance, and orthopedic disorders, resulting in crouch gait in about two-thirds of the children, but this was severe in only 11%, and all children were still able to walk. They all presented with intellectual disability, considered moderate in 58% of cases. Most children exhibited behavioral disorders (88%), mainly aggressiveness (43%), autistic traits (31%), or apathy (26%), but these disorders were rarely severe (11% of cases). More than 90% of children regularly attended an adapted structure of care and benefited from rehabilitation, and 70% were at least partially autonomous in everyday life.
| RESULTS
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The seven patients not yet on STP were all receiving valproate and six were on clobazam, at a mean dose of 22 and 0.5 mg/kg/d, respectively; carbamazepine, phenytoin, lamotrigine, and phenobarbital were still associated in one case each. In contrast with the patients treated with STP, none was seizure-free, only 40% had <1 GTCS/wk, and all had abnormal neurological examination.
| Last visit before adulthood
All 40 patients were on STP at this time (median age = 17.7 years; Tables 2 and 3 ). They received a median dose of 34 mg/kg/d. Altogether, they had a median STP exposure of 11 years, but whereas it reached 13 years for the 33 early treated patients, it was <1 year for the seven late treated patients. STP had been interrupted within the previous months in two patients (for anorexia and loss of weight in one case, for persisting seizures in the other) but promptly reintroduced in both due to seizure worsening. As comedication, all patients received clobazam, all but one valproate (withdrawn in a patient with mild intellectual disability because of child-bearing age), and 45% topiramate, at a median dose of 0.3, 13, and 2.2 mg/kg/d, respectively. As recommended, for the seven patients who started STP after childhood, valproate and clobazam dosages had been decreased compared to the doses given at 15 years of age (Table 3) . Levetiracetam, clonazepam, or phenytoin were associated in no more than four cases. New significant adverse events were reported in four patients. In two cases, they were STP-related (anorexia with a weight loss of 6 kg, asymptomatic neutropenia [white blood cells <1000/mm 3 ]) and resolved when the STP dose was decreased; in another case, they were related to topiramate and levetiracetam that were withdrawn; the remaining patient presented with hypothyroidism diagnosed between 15 and 18 years of age. At this visit, two patients had had no GTCSs for respectively 1 and 2.7 years. Compared to the previous visit before age 15 years, some patients (<15%) still displayed seizures other than GTCSs, and four had had status epilepticus. The proportion of patients whose GTCSs occurred less than once per week and lasted <1 minute was also quite stable (at 50% and 77%, respectively) as were the other seizure characteristics, except alternating seizures, which were no longer observed.
Despite a similar proportion of institutional and rehabilitation attendance as at the previous visit, the rate of neurological disorders (namely hypotonia and crouch gait) now reached 74%, with 31% having severe cases (one scoliosis surgery). Nevertheless, all patients could still walk. Regarding intellectual disability, severity remained in the same range (43% vs 39%). By contrast, the proportion of severe behavioral disorders had increased (38%) and 10% required neuroleptic treatment. As a result, 47% of patients had become totally dependent for everyday life. Most of them (91%) were living in adapted institutions with access to rehabilitation.
| Last visit in adulthood
At this final visit (median age = 23 years, up to 40 years), all 40 patients were still on STP, with a median exposure of 18 years (up to 24 years) and a median dose of 25 mg/kg/d, significantly lower than just before adulthood (P = 0.0002; Table 2 ). The dose of STP had been progressively decreased from adolescence on, whereas that of clobazam, valproate, and topiramate had remained remarkably stable ( Figure 1 ). STP had been interrupted between 18 and 25 years in three patients (for anorexia and loss of weight in one case, for persistence of seizures in the other two, although frequency was stable and relatively low), but needed to be promptly reintroduced in all three because of seizure aggravation. Comedication was the same as before adulthood (40 on clobazam, 39 on valproate, 20 on topiramate), and the dose was unchanged. Zonisamide was associated in five patients, levetiracetam in four.
Twenty-two significant adverse events appeared in 18 of 40 patients during adulthood. Sixteen of them were STP-related (anorexia with loss of weight in 15 cases, up to 10 kg in one patient, recurrence of myoclonus when increasing the dose in one case). In all cases, appetite became normal with a decrease in the dose of STP (transiently stopped in one case) and valproate (in five cases, stopped in one). Decreasing the STP dose sometimes resulted in a progressive increase in seizure frequency that required reincreasing the STP dose. This repeat adaptation of the STP dose from childhood up to the age of 30 years was required in at least five patients. The other adverse events were hallucinations (two cases) and gynecomastia (one case, resulting in mastectomy in a male patient) for those reported between 18 and 25 years of age and hypothyroidism (one case), thrombopenia (one case, solved by decreasing the valproate dose), and rectal hemorrhage (one case, solved by decreasing the topiramate dose) for those reported after 30 years of age. One patient died at 25 years of age from a cause unrelated to DS.
At this visit, three patients were seizure-free. During adulthood, altogether 10 patients exhibited periods of at least 1 year without GTCSs (median = 2 years, up to 4.7 years). Compared to the last visit before adulthood, status epilepticus had disappeared (no case after 25 years of age), myoclonus had become exceptional (one patient), and other seizures remained rare. Concomitantly, the proportion of patients for whom GTCS frequency was <1/wk and duration was <1 minute had risen to 68% and 90%, respectively, and median GTCS frequency during the last month had significantly decreased (P = 0.02). The other GTCS characteristics and EEG features remained unchanged from the end of childhood.
Severe hypotonia and crouch gait now affected nearly half the patients (46%), and two had lost the ability to walk. Intellectual disability was significantly more severe than at the last visit before adulthood (P = 0.03) and almost all patients (92%) exhibited behavioral disorders, which were considered severe in 57% of cases. As a result, half the patients were totally dependent, with an increasing proportion failing to find any adapted institution and having to stay at home (23%) without any rehabilitation possibility (28%, P = 0.07).
| Subpopulations and longitudinal course
Regarding age at STP initiation (Table 3) , the early treated patients (from infancy to childhood, median onset = 6 years, designated "STP before 15 years") tended to present with better outcome in adulthood than the late treated patients (at late adolescence, median = 19 years, designated "STP after 15 years"), although the late treated sample was too small to detect any statistical significance. At the last visit, seizure frequency and duration tended to be lower in the former than in the latter (the three seizure-free cases had been treated early). Conversely, neurological disorders, behavioral comorbidities, and severe intellectual disability involved 100% of the late treated patients (the two who lost the ability to walk were in this group), whereas about 40% of the early treated patients exhibited less severe disorders (Table 3 ). Longitudinal data confirmed that the GTCS frequency and duration of both groups continued to progressively decrease along adulthood on STP, but the late treated patients presented a less favorable profile during the whole course (Figure 2 ). Although their seizure frequency had been especially high in late adolescence, it rapidly dropped when STP was started. However, 20 years later on STP they continued to have more seizures than the others (Figure 2A, Table 3 ). Similarly, comorbidity was more severe in the late than the early treated group (Figure 3) , although early STP initiation did not prevent the neurological/intellectual/behavioral condition from continuing to decline in adulthood.
Regarding typical (n = 32) and atypical (n = 8) DS patients, the former unsurprisingly tended to exhibit a more severe profile than the latter. All cases of status epilepticus reported from age 15 years involved typical patients, and they tended to present with more frequent and longer GTCSs than atypical patients in the course of adulthood (GTCS frequency < 1/wk from 47% to 63% vs from 63% to 88%, GTCS duration < 1 minute from 70% to 94% vs from 57% to 75%). In addition, no atypical patient reported focal or tonic seizures since the age of 15 years. Typical patients presented with higher rates of neurological disorders than atypical patients during adulthood (from 72% to 83% vs from 43% to 57%, respectively), and the two who lost the ability to walk were typical cases. Similarly, behavioral disorders tended to be more frequent in typical than atypical cases (from 86% to 94% vs from 63% to 88%) and the proportion of patients without rehabilitation tended to be higher (from 7% to 31% vs from none to 13%).
| DISCUSSION
In this historical monocenter cohort of DS patients treated with STP from childhood or adolescence, the efficacy and the safety of STP were maintained in the long term in adulthood with up to 24 years of exposure, provided the dose of STP was progressively decreased and that of clobazam and valproate comedication remained unchanged. Seizure frequency and duration continued to significantly decrease in adulthood, status epilepticus completely disappeared, and 25% of patients experienced seizure-free periods of >1 year in adulthood. Although the spontaneous improvement of epilepsy in adulthood of DS patients has been reported by several studies, the present data nevertheless suggest that STP by itself has a favorable impact on this evolution. First, epilepsy outcome was less severe when STP had been initiated from childhood. Second, whenever STP was interrupted during adulthood it had to be reintroduced following seizure aggravation, so that all patients were still on STP at the last visit in adulthood. Finally, even if neurological, cognitive, and behavioral disorders continued to worsen as expected, they tended to be less severe in the long range if STP had been started before adolescence.
| Very long-term treatment with STP and how to use it in adults
Many long-term series are available in children that include at least 15 DS patients (up to 82) treated for >1 year with STP.
4,14,17-20 Overall, 44%-54% of patients were still responders to GTCSs for 1-8 years and the number of episodes of status epilepticus decreased with age. 4, 14, 20 However, only early adulthood is documented, the oldest patients being 22 years. 14, 20 The present cohort is the first one in which STP was continued after the age of 25 years and that gives details regarding the longitudinal course through adulthood. Efficacy is still maintained after a median of 18 years on STP and up to 40 years of age. Remarkably the proportion of patients who experienced prolonged seizure-free periods (25% >1 year, 13% >2 years, up to 4.7 years) is the highest ever reported in DS. Also note that all the attempts to withdraw STP in adulthood resulted in a worsened seizure condition and STP reintroduction was successful in all cases. It is therefore beneficial for DS For these patients, it was also beneficial to continue the same comedication as during childhood, that is, clobazam, valproate, and at the same adapted doses, that is, half dose without STP. By contrast, the optimal dose of STP may be lower in adults than in children. This is in agreement with the pharmacokinetic data in healthy and DS adults 21, 22 and with recommendations to decrease the dose with increasing age from infancy to adolescence. 1 As in childhood, the most common adverse event of STP in adulthood is loss of appetite/loss of weight, reported in about two-thirds of cases in the literature and usually resolved by diminishing the dose. 11, 17, 20 The same applies to the present cohort, but with a lower incidence (40%) possibly due to the systematic optimization of the dose of STP and valproate.
| The benefit of STP treatment on the late outcome
To what extent a given antiepileptic drug may impact the natural outcome of DS remains an open question; true longitudinal studies are rare, and valuable comparative data are exceptional. Through childhood, DS features are known to become "stable" from about 6 years of age on, following the so-called "febrile" and "worsening" stages. 23 STP treatment improved the epilepsy condition at pediatric age, 2, 3 especially by reducing the number of prolonged seizures, 4, 14, 20 despite the unaltered course of the genetic encephalopathy. 24, 25 Long-term outcome in adulthood is more sparsely described, but all the series collected before the era of STP agree that epilepsy tends to be increasingly less severe, whereas the neurological/intellectual condition continues to decline. 7, 8, 10, 26 The duration of aggravating medication use and age at first afebrile seizure were recently identified as predictors for cognitive outcome in a large Dutch cohort of 116 DS patients followed up to 48 years (median = 14 years), but seizures and other treatment data are not reported. 27 The Japanese cohort of DS patients provides therefore the only actual longitudinal data available so far from childhood to late adulthood (age = 19-45 years, median = 30 years). 10 disappearance of status epilepticus, the same rate of seizure remission (8%), and the same rate of severe intellectual disability (77%), seizure frequency is lower in our cohort (32% vs 47% of patients with >1 seizure/wk). Because the Japanese series has a higher rate of atypical DS than our cohort (0.5 vs 0.2), it is expected to have better outcome, as atypical cases are known to exhibit a significantly less severe phenotype. The tendency for better seizure outcome in our cohort is an additional argument for a positive impact of STP on seizures in the long term in adult patients with DS.
| The benefit of STP treatment when initiated from childhood
Among the series of adult DS patients reported, very few have received STP (19/152), but they all experienced a drastic decrease in GTCS frequency despite the late initiation of treatment (age = 19-30 years). [5] [6] [7] By contrast, only three of 13 patients responded in another series with late STP introduction (age = 12-17 years, mean = 26 years), but they had all received potentially aggravating drugs for long periods due to delayed diagnosis of DS. 11 Conversely, they presented with a more severe epilepsy at the age of STP introduction: still daily to weekly seizures and episodes of status epilepticus (62% of cases), compared to weekly to monthly seizures and <20% of cases having status epilepticus at the same age in DS patients diagnosed early and appropriately treated from childhood, even if STP-naive. 10 Note that in our cohort, the late treated subpopulation presented at the entry to adulthood with a rate of seizure frequency and status epilepticus in the same range as Takayama's patients. 10 According to our data, DS patients do benefit from receiving STP as early as childhood, but the late treated sample (from adolescence) was too small to detect any statistical significance compared with the early treated one. Based on human and experimental studies, the earlier the STP initiation, the better the effect, especially on seizure duration and therefore on the prevention of status epilepticus. 4, [28] [29] [30] However, this does not completely exclude any benefit of initiating STP in adulthood: for instance, to prevent status epilepticus and to treat refractory forms. 31, 32 Two cases of motor and intellectual improvement were even reported after initiating STP and optimizing comedication at >40 years of age. 9 Optimization consisted in particular in withdrawing drugs reported as aggravating in pediatric patients with DS, such as sodium channel blockers, vigabatrin, and high doses of phenobarbital. 4, 33, 34 However, stopping very long-lasting treatment in such disabled adults may also result in withdrawal symptoms; thus, the procedure should be carefully monitored. 35 In addition, lamotrigine may occasionally be beneficial in adult patients with DS. 
| Methodological issues
Although the heterogeneity of the data was minimized (one center, three main investigators) and the whole population eligible in the center was included, our study has the limitations of being retrospective and descriptive. Determining the impact of STP per se in outcome is not possible based on the present data; that would have required a comparative cohort not treated with STP, which was not available at our center (>95% of DS patients are on STP from an early age 14 ) . As an attempt to put our data into perspective with those of STP-naive patients, we used Takayama's cohort, 10 because it was the closest to our practice (age at diagnosis, clinical care, caution regarding aggravating drugs); however, it included twice as many atypical (therefore less severe) patients and not all our items were available. Finally, our subgroups probably were too small to detect any significant difference on statistics (STP initiated <15 years vs >15 years, typical vs atypical).
| CONCLUSION
Nearly 20 years of exposure to STP from childhood contributed to improving epilepsy prognosis at midadulthood in the French historical cohort of DS patients. Such continuing seizure reduction seemed to slightly limit the severity of comorbidity, although it could not prevent genetic encephalopathy from progressing. It was therefore beneficial for these satisfactorily controlled DS adolescents to maintain STP at the transition to adult care and during adulthood, at a dose progressively decreased to 25-30 mg/kg/d and with unchanged comedication. In addition, these patients treated from pediatric age tended to present with better seizure outcome in adulthood than patients from other series treated from adult age or who were STP-naive.
